Results 61 to 70 of about 6,366 (244)

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

State of Vegetative Homeostasis in Children with Anthracycline-Induced Cardiomyopathy

Zdorovʹe Rebenka, 2014
The paper presents the results of investigation of the autonomic nervous system in children with acute lymphoblastic leukemia, in whom as a result of protocol chemotherapy with anthracycline antibiotics application, toxic anthracycline-induced ...
T.V. Shatynska, O.B. Synoverska, S.B. Shkandriy   +2 more
doaj   +1 more source

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

, 2014
One of the most important adverse effects of anthracyclines is cardiotoxicity. A well-informed decision on the use of anthracyclines in the treatment of childhood cancers should be based on evidence regarding both antitumour efficacy and cardiotoxicity ...
Martine F Raphaël, Huib N Caron, Leontien CM Kremer, Raphaël, Martine F., Caron, Huib N., Kremer, Leontien C. M., Elvira C van Dalen, van Dalen, Elvira C.   +7 more
core   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Functional investigation of the SAM-dependent methyltransferase RdmB in anthracycline biosynthesis

Synthetic and Systems Biotechnology
A novel sub-class of S-adenosyl-l-methionine (SAM)-dependent methyltransferases catalyze atypical chemical transformations in the biosynthesis of anthracyclines.
Moli Sang, Qingyu Yang, Jiawei Guo, Peiyuan Feng, Wencheng Ma, Wei Zhang   +5 more
doaj   +1 more source

Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression

Pteridines, 2013
Sensitivity to antifolates can be decreased by endogenous or exogenous folates. Leucovorin protects cancer patients against toxicity of the dihydrofolate reductase inhibitor methotrexate (MTX), while folic acid is used to protect rheumatoid arthritis ...
Peters Godefridus J., Kathmann Ietje, Lemos Clara, Hooijberg Jan Hendrik, Losekoot Nienke, Jansen Gerrit   +5 more
doaj   +1 more source

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

, 2009
Background One of the most important adverse effects of anthracyclines is cardiotoxicity. A well-informed decision on the use of anthracyclines in the treatment of different types of childhood cancer should be based on the available evidence on both ...
Martine F Raphaël, Huib N Caron, Leontien CM Kremer, Raphaël, Martine F., Caron, Huib N., Kremer, Leontien C. M., Elvira C van Dalen, van Dalen, Elvira C.   +7 more
core   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Synthesis of Anthracyclines

Synthetic efforts towards anticancer anthracyclines are described (including PhD thesis investigations) as well as theoretical chemistry involved mainly with selected dienophiles and dienes in associated Diels-Alder reactions.
Miller, Jonathan
core   +2 more sources

Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance

, 2023
1. ABCB1 (P-glycoprotein, MDR1) is one of the most important transporter involved in cancer multi-drug resistance. It also plays a significant role in cancer resistance against anthracyclines, an anticancer group of drugs, including doxorubicin and ...
Kamil Piska (6541331), Paulina Koczurkiewicz-Adamczyk (9981364), Elżbieta Pękala (2856101), Marcin Kołaczkowski (805225), Marek Jamrozik (17121252), Adam Bucki (805224)   +5 more
core   +1 more source